EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer

EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer
Rubraca (rucaparib) is a step closer to availability in Europe for ovarian cancer patients with relapsed or progressive disease. The E.U.’s Committee for Medicinal Products for Human Use (CHMP) recently supported the approval of the treatment. CHMP’s positive opinion recommends conditional marketing authorization for Rubraca in patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *